2022
DOI: 10.3390/cancers14215422
|View full text |Cite
|
Sign up to set email alerts
|

Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives

Abstract: Cholangiocarcinoma represents a heterogeneous disease at both a clinical and molecular level [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 33 publications
0
3
0
Order By: Relevance
“…Interestingly, we documented the selective modulation of only twenty proteins, ten upregulated and ten downregulated. We observed the upregulation of key oncogenes described in other tumoral models, such as PN1 [ 28 ] and NDUFC1 [ 30 ], while, on the other hand, we found downregulation of the crucial tumor suppressors PP2A [ 29 , 31 , 35 ], ENO3 [ 32 ] and NOTCH3 [ 33 ]. Among the modulated proteins, collagen VII was detected only in HuCC-T1 lysates from cocultures, suggesting the modulation of TGFβ signaling.…”
Section: Discussionmentioning
confidence: 76%
See 1 more Smart Citation
“…Interestingly, we documented the selective modulation of only twenty proteins, ten upregulated and ten downregulated. We observed the upregulation of key oncogenes described in other tumoral models, such as PN1 [ 28 ] and NDUFC1 [ 30 ], while, on the other hand, we found downregulation of the crucial tumor suppressors PP2A [ 29 , 31 , 35 ], ENO3 [ 32 ] and NOTCH3 [ 33 ]. Among the modulated proteins, collagen VII was detected only in HuCC-T1 lysates from cocultures, suggesting the modulation of TGFβ signaling.…”
Section: Discussionmentioning
confidence: 76%
“…It also inhibits EMT by dephosphorylating β-catenin and allowing its degradation to occur [ 29 ]. In CCA, and more specifically HuCC-T1 cells, the role of PP2A as an inhibitor of EMT, invasiveness and proliferation has been clarified [ 31 , 35 ]. Notably, PP2A inhibits TGFβ signaling by TGFBR1 dephosphorylation, and downregulation of PP2A in prostate cancer leads to enhanced TGFβ signaling [ 36 ].…”
Section: Discussionmentioning
confidence: 99%
“…In the liver, PP2A inactivation has been predominantly associated with HCC [ 31 , 32 , 33 ] and less frequently, with CCA [ 34 ]. However, the clinical picture remains largely incomplete and the impact of PP2A inhibition on the efficiency of (targeted) PLC therapies remains unresolved.…”
Section: Introductionmentioning
confidence: 99%